spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Azixa 

 HSMN NewsFeed - 27 Jan 2017
Immune Pharmaceuticals Appoints New Chairman of the Board of Directors
Biopharmaceuticals Gastroenterology Oncology Personnel
 HSMN NewsFeed - 20 Aug 2013
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Feb 2013
EpiCept Corporation and Immune Pharmaceuticals Amend Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 5 Sep 2012
EpiCept Regains Rights to Azixa(R) from Licensee Myrexis
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 23 Jan 2012
EpiCept Corporation Receives Finalized FDA Guidance for AmiKet(TM) Phase III CIPN Program and Regulatory Strategy
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Mar 2011
EpiCept Identifies Ceplene(R) Survival Benefit in Key AML Subgroup
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2010
EpiCept Announces Ceplene(R) Approved for Marketing in Israel
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Dec 2010
EpiCept Announces Initiation by NCI of Phase II Trial with Crolibulin(TM) in Anaplastic Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Oct 2010
EpiCept Corporation and FDA Agree on Development Plan for Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jul 2010
EpiCept Amends Employment Agreement and Completes Severance Agreements with Executive Officers
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2010
EpiCept Corporation Names Rita Kelley Senior Director of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2010
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2010
EpiCept Corporation Announces Commercial Launch of Ceplene(R) in Germany
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Apr 2010
EpiCept Announces Commercial Launch of Ceplene(R) in the United Kingdom
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Jan 2010
EpiCept Receives Orphan Drug Designation for EpiCept NP-1 in U.S.
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2010
EpiCept Announces Commercial Licensing Agreement for Ceplene(R) with Meda in Europe and Pacific Rim
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Dec 2009
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Nov 2009
EpiCept Corporation Names Bernard Tyrrell as Senior Vice President, Sales and Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jul 2009
EpiCept Initiates Post-Approval Clinical Study with Ceplene(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2009
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2009
Myriad Applauds New ACOG Guidelines for Hereditary Breast and Ovarian Cancer
Diagnostics Oncology
 HSMN NewsFeed - 9 Oct 2008
EpiCept Receives Ceplene(R) Marketing Approval in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Sep 2008
EpiCept Amends DURECT Bupivacaine Patch Licensing Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 25 Jul 2008
Ceplene(R) Receives Positive European Opinion for Approval From CHMP
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 12 Jun 2008
EpiCept Releases New Ceplene AML Data Demonstrating Leukemia Free Survival as Predictor of Improved Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 May 2008
EpiCept Files Re-Examination Documentation for Marketing Authorization of Ceplene(TM) in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Mar 2008
EpiCept Announces Opinion by European Regulatory Authority on Ceplene(R)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Feb 2008
EpiCept Announces Non-Binding Opinion by European Regulatory Authority on Ceplene Marketing Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Feb 2008
EpiCept Announces Encouraging Results of Phase II Trial for NP-1 Cream in Diabetic Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2008
Myriad Genetics, Inc. Expands Commercial and Clinical Infrastructure
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2007
EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2007
Myriad Genetics Submits IND on Vivecon
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 18 Sep 2007
EpiCept Reports Regulatory Progress on Ceplene(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Aug 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jul 2007
EpiCept Announces Phase III Study of EpiCept(TM) NP-1 for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Biopharmaceuticals
 HSMN NewsFeed - 19 Jul 2007
EpiCept Establishes Direct Licensing Agreement with Dalhousie University for EpiCept(TM) NP-1
Biopharmaceuticals Licensing
 HSMN NewsFeed - 27 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa in Metastatic Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2007
Myriad Genetics Initiates Phase 2 Clinical Trial of Azixa(TM) in Brain Cancer
Biopharmaceuticals Oncology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.